Patient-reported Barriers to Osteoporosis Therapy
Overview
Affiliations
Purpose/introduction: Osteoporosis patients commonly cite treatment-related side effects, or the fear thereof, as a reason for discontinuing or not initiating anti-osteoporosis medications. The purpose of this study was to investigate, from the patient's perspective, reasons for (i) non-treatment of osteoporosis and (ii) discontinuation of osteoporosis therapy.
Methods: This was an internet-based survey of postmenopausal women in the USA who self-reported having been diagnosed with osteoporosis. Respondents were recruited from consumer research panels and received nominal compensation.
Results: Within the surveyed population (N = 1407), 581 patients were currently being treated, 503 had never been treated, and 323 had previously been treated. Among patients never treated for osteoporosis, the highest ranking reasons for non-treatment were the use of alternative treatments such as over-the-counter vitamins/supplements (57.5 % of respondents) and fear of side effects (43.9 %). Among previously treated patients, frequent reasons for discontinuation included the direction of the physician (41.2 % of respondents), concerns about long-term safety (30.3 %), and the experience of side effects (29.8 %). When asked about their willingness to restart their osteoporosis medication, previously treated patients who were not willing (N = 104) to restart had a higher frequency of experiencing side effects (44.2 versus 20.5 % of those willing; P < 0.001).
Conclusions: From the osteoporosis patient's perspective, barriers to prescription treatment include a preference for alternative, non-prescription treatments and a fear of possible side effects. Side effects are one of the most common reasons for discontinuing osteoporosis medications, and they appear to be associated with a lack of willingness to restart treatment.
Nutraceuticals in osteoporosis prevention.
Roseti L, Borciani G, Grassi F, Desando G, Gambari L, Grigolo B Front Nutr. 2024; 11:1445955.
PMID: 39416651 PMC: 11479890. DOI: 10.3389/fnut.2024.1445955.
Rezae F, Kelly A, Dey S, Moles R, Carter S Arch Osteoporos. 2024; 19(1):8.
PMID: 38191760 DOI: 10.1007/s11657-023-01359-y.
Yang Q, He J, Yuan F Osteoporos Int. 2023; 35(2):309-316.
PMID: 37801081 PMC: 10837216. DOI: 10.1007/s00198-023-06933-1.
Sun C, Chen M, Wang X, Qi B, Yin H, Ji Y BMC Complement Med Ther. 2023; 23(1):325.
PMID: 37716968 PMC: 10504697. DOI: 10.1186/s12906-023-04161-y.
Vuong T, Peters M, Merrifield A, Firipis M, Belcher J, Elgebaly Z Arch Osteoporos. 2023; 18(1):90.
PMID: 37405619 DOI: 10.1007/s11657-023-01301-2.